8-K
filed May 18, 2023, 7:59 PM ET
ticker FLGT
CIK 0001674930
other material
confidence high
sentiment neutral
materiality 0.45
Fulgent Genetics stockholders approve 3M share increase to 2016 Incentive Plan
Fulgent Genetics, Inc.
- Stockholders elected all four director nominees: Ming Hsieh, Michael Nohaile, Regina Groves, Linda Marsh.
- Ratified Deloitte & Touche LLP as independent auditor for fiscal year 2023.
- Advisory vote approved executive compensation with 18.9M for and 0.6M against.
- Amended 2016 Omnibus Plan approved to increase shares reserved by 3M (10.8M for, 8.7M against).
- Plan amendment adds 3M shares, representing ~10% dilution relative to 29.7M shares outstanding.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Fulgent Genetics, Inc. shareholders approved Election of directors at the 2023-05-18 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
Proposal 1 Election of the following nominees as directors of the Company, each to serve until the 2024 Annual Meeting and until his or her successor is duly elected and qualified.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Fulgent Genetics, Inc. shareholders approved Approval of an amendment and restatement of the Company’s 2016 Omnibus Incentive Plan increasing the number of shares of common stock reserved for issuance thereunder by 3 million shares at the 2023-05-18 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
Proposal 4 Approval of an amendment and restatement of the Company’s 2016 Omnibus Incentive Plan increasing the number of shares of common stock reserved for issuance thereunder by 3 million shares.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Fulgent Genetics, Inc. shareholders approved Approval, on a non-binding advisory basis, the compensation of our named executive officers at the 2023-05-18 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
Proposal 3 Approval, on a non-binding advisory basis, the compensation of our named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Fulgent Genetics, Inc. shareholders approved Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-05-18 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-18
Exact text from the filing
Proposal 2 Ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.